Document is current

Article History

Received: 22 February 2021

Accepted: 14 June 2021

First Online: 8 July 2021

Declarations

:

: This study was approved by the Chelsea & Westminster NHS Foundation Trust COVID testing committee. The study was reviewed by the Chelsea & Westminster NHS Foundation Trust Research and Development Office and deemed a verification of a CE marked in vitro diagnostic test, therefore the need individual informed consent was waived. Aggregated data was analysed in accordance to the UK Secretary of State for Health and Social Care general notice that under the Health Service Control of Patient Information Regulations (2002) patient data for a COVID-19 purposes may be used for research. The study was conducted in accordance with relevant guidelines and regulations including the Declaration of Helsinki.

: All authors consent to publication of this manuscript in this journal. This work has not been previously published in any other journal.

: AB, CT, RS, NC, AM, MS, MK, T-KH and JB are employees of DnaNudge. CT is the co-inventor of the DnaNudge CovidNudge system and is named on the patent for the method and apparatus for analysing biological specimens on the DnaNudge platform (US Patent No: US 10 093 965.B2). LSPM has consulted for and/or received speaker fees from bioMerieux (2013–2021), Pfizer (2018–2021), Eumedica (2016–2021), Umovis Lab (2020–2021), Shionogi (2021), Pulmocide (2021), DNAelectronics (2015–18), and Dairy Crest (2017–2018), received research grants from the National Institute for Health Research (2013–2019), and CW+ Charity (2018–2021). GC is an NIHR research professor and investigator within the NIHR London in-vitro diagnostic co-operative. All other authors declare no competing interests.